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imaging approaches (7–9). The albumin-specific magnetic
resonance (MR) probe, gadofosveset trisodium, investi-
gated in this study is clinically approved in the European
Union and the U.S. (8,9). After intravenous administra-
tion, gadofosveset trisodium reversibly binds to serum
albumin. This results in a prolonged serum half-life and
an up to 10-fold increase in T1 relaxivity of the probe
(8,9). Therefore, this probe can be detected by CMR with
a much higher sensitivity compared with other clinically
used contrast agents, such as gadovist. Bound to albumin,
this probe was shown to have properties comparable with
Evans blue dye, which represents a surrogate marker for
endothelial permeability in the arterial system (8,9). Prior
studies in a murine model of atherosclerosis have dem-
onstrated that gadofosveset trisodium accumulation
reflects the degree of endothelial leakiness and gap junc-
tion width (8,9).
The aim of this study was to test the potential of
gadofosveset trisodium as a novel in vivo biomarker for
the evaluation of endothelial permeability in patients with
different HbA1c levels.
RESEARCH DESIGN AND METHODS
Study Population
The study population consisted of patients with different
HbA1c levels, who were prospectively enrolled between
April 2015 and June 2016. Inclusion criteria were age
between 18 and 99 years and clinical indication for in-
vasive X-ray coronary angiography (XCA) owing to symp-
toms of stable coronary artery disease (CAD) or acute
coronary syndrome (unstable angina and non–ST elevation
myocardial infarction). Patients were stratified into three
groups based on HbA1c level: low (,5.7% [,39 mmol/mol]),
intermediate (5.7–6.4% [39–47 mmol/mol]), or high
($6.5% [$48 mmol/mol]). HbA1c measurements were
performed in EDTA anticoagulated blood samples
at the time of admission. Hemodynamically unstable
patients, such as patients with cardiogenic shock, rising
cardiac enzymes or malignant cardiac arrhythmias, or ST
elevation myocardial infarction; pregnant women; patients
with a history of coronary stenting; patients with renal
insufficiency (creatinine clearance ,30 mL/min); and
patients who were not able to give written consent either
because of age (,18 years of age) or because of mental
disorders were excluded. Further exclusion criteria in-
volved common contraindication to CMR (allergy to
gadolinium-based contrast agents, claustrophobia, or spe-
cific metallic items such as cochlear implants, central
nervous system aneurysm clips, or pacemakers/defibrilla-
tors). Patients underwent a CMR sequence consisting of
a native CMR scan and a gadofosveset-enhanced CMR
exam (both exams within 24 h). The following day, XCA
and optical coherence tomography (OCT) was performed. The
study was approved by the local ethics committee for clinical
investigations and was performed in accordance with the
Declaration ofHelsinki. All patients providedwritten informed
consent.
CMR
Allsubjectswerescannedinthesupinepositionina3-Tesla
MRI scanner (MAGNETOM Skyra; Siemens Healthcare,
Erlangen,Germany).Continuousmonitoring of vital signs
throughout the entire CMR scan was performed with
a four-leadelectrocardiogram. Inpatientswith elevated
troponin levels,aCMR-compatiblebloodpressuremon-
itorandbloodoxygenationsensorwasusedinaddition.
Gadofosvesettrisodium(doseof0.03mmol/kgbodywt)
wasadministeredintravenouslythroughacatheterinan
antecubitalveinfollowingthefirst imagingsession.Sig-
nal enhancement, as defined by the contrast-to-noise
ratio(CNR)(SupplementaryData)ofcoronarysegments
was determined according to the nine-segment model.
CNR was obtained by dividing the difference in signal 
intensity(SI)betweenthecoronarysegmentandbloodby
thebackgroundnoise (SI lesion SIblood)/noise.Seg-
mentscontainingaculpritlesiondiscoveredinXCAwere
excluded from later analysis.TheCMR intensitieswere
set in relation to the intensities from the aorta, i.e.,
normalized. The goal of this preprocessing step is to
make the intensities between the different patients
more comparable. Additionally, we extend the model
by the available covariates. These are included as addi-
tionalfixedeffects in themodel.
XCAandOCT
XCAwasperformedwithin24hafterCMRaccording to
standard techniques via a transradial or transfemoral
approach. Whenever possible, two orthogonal views
were acquired for all coronary arteries. OCT (Ilumien,
OCT system; St. Jude Medical, Minnesota, MN) of the
coronaryarterywiththehighestgradeofstenosisorthe
largestamountofplaquewasperformedafterXCA.
OCT ImageAnalysis
OCT frames were assessed by two experienced readers
(M.J. and L.-C.E.), who were blinded to the CMR data
sets, using proprietary software (St. Jude Medical). In
case of disagreement between the two OCT readers,
consensusreadingwasperformedbyathirdinvestigator
(B.B.). Plaqueswere evaluated using validatedOCT cri-
teria (10). Segments were stratified into two different
categories: segments with late atherosclerotic lesions
(LALs)(calcifiedandnoncalcifiedfibroatheromaandcal-
cifiedandnoncalcified thin-capfibroatheroma)andseg-
ments without these high-risk lesions (i.e., early
atherosclerotic lesions [EALs], including healthy vessel
wall, pathological intimal thickening, and fibrous and
fibrocalcific plaque (11).
Statistics
Groupdifferences inMRI signal enhancementwere an-
alyzed by hierarchical regression models within a fully
Bayesian setup (12). Formulation of these models can
be divided into structural and distributional assump-
tions; i.e., information needs to be provided for ef-
fects of interest and covariates as well as for the
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and 0.71 ( 2.42 to 2.71). With use of a Bayesian frame-
work, there were similar values regarding normalized SIs
between the groups in the non–contrast-enhanced sequen-
ces (see Fig. 1). With respectQ:7 to gadofosveset-enhanced
sequences, the group with HbA1c levels between 5.7 and
6.4% had an average of 0.30 increased normalized SI (95%
CI 0.04, 0.57) compared with the group with HbA1c
levels ,5.7%. For patients with HbA1c levels $6.5%, we
recorded an average of 0.57 increased normalized SI (95%
CI 0.28, 0.85) compared with the healthy group (HbA1c
levels ,5.7%). Additionally, we found a 0.26 higher SI for
patients with HbA1c level $6.5% compared with patients
with HbA1c levels between 5.7 and 6.4% (0.26 [95%
CI 0.04, 0.57]) (Fig. 1).
The probability that high and intermediate HbA1c levels
were associated with higher CNR values compared with low
HbA1c levels was 1.00 and 0.99, respectively, whereas the
corresponding probability was 0.95 for patients with high
versus intermediate HbA1c levels. Corresponding differences
were less for the non–contrast-enhanced CMR (Fig. 1).
Invasive XCA
In the entire patient cohort, 53.8% of patients had no CAD.
These patients were diagnosed with either microvascular
disease or noncardiac chest pain (i.e., musculoskeletal).
CMR Signal Enhancement and Distribution of EALs
and LALs
Contrast-to-noise estimates for EALs and LALs were 2.39
(0.89–3.93) and 3.76 (2.17–5.29), respectively (Fig. 2A).
Given the available data, the probability that LALs showed
higher mean CNR values, compared with EALs, was 0.93 in
gadofosveset-enhanced and 0.40 in native, non–contrast-
enhanced CMR (Table 2).
In the subgroup of segments that were visualized Q:8on
OCT (i.e., culprit vessel), LALs were more common in
patients with high HbA1c levels ($6.5%, n = 14 [74%];
5.7–6.4%, n = 6 [60%]; and,5.7%, n = 10 [53%]) (Figs. 2B
and 3). Probabilities and odds ratios for the presence of
LALs are seen in Supplementary Data.
DISCUSSION
We demonstrated that patients with low HbA1c lev-
els, ,5.7%, showed notably less signal enhancement
compared with patients with HbA1c levels above that
threshold after application of an albumin-binding MR
probe. This probe is considered a surrogate marker of
endothelial damage in the arterial system. Notable differ-
ences in terms of signal enhancement could already be
observed between the low and intermediate HbA1c group.
This could be of clinical relevance, as it indicates that
patients with slightly elevated HbA1c levels may already
have significant vascular impairment and, consequently,
an increased risk for CAD.
Additionally, our subanalysis revealed that there was
a considerable probability, of 0.93, that LALs, as
assessed using invasive OCT, were associated with
higher signal enhancement (i.e., CNR values) after ap-
plication of an albumin-binding probe compared with
EALs. Patients with high HbA1c levels are known to
have a more aggressive development of atherosclerosis,
resulting in a worse cardiovascular outcome (3). In line
Figure 1—Comparison of normalized CMR SIs between the three different groups in gadofosveset-enhanced and native CMR scans. Here,
we demonstrate the so-called posteriori P values (see horizontal brackets), which report the probability that there is a difference between the
groups. For instance, in looking at the contrast-enhanced scans, the probability that high and intermediate HbA1c levels in patients were
associated with higher CNR values compared with low HbA1c levels was 1.0 and 0.99, respectively, whereas the corresponding probability
was 0.95 for patients with high vs. intermediate HbA1c levels.
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probe that was initially developed and used as a blood
pool agent for high-resolution steady-state angiography
(8,9). In subsequent experimental and human studies, it
was demonstrated that this probe could also be useful
as a surrogate marker for endothelial permeability and
damage (8,9).
The direct visualization of endothelial damage and
permeability using gadofosveset-enhanced CMR could
be regarded as an alternative in vivo parameter for
cardiovascular risk prediction in patients with elevated
HbA1c levels and monitoring of therapeutic strategies
that have positive effects on the endothelium. For
instance, therapeutic strategies such as the use of
statins, insulin analogs, antihypertensive medication,
and hypoglycemic agents have been shown to have
a beneficial effect on diabetes associated vascular im-
pairment (16).
This study has some limitations. The main limitation
of this study is that endothelial function was not
assessed directly, e.g., by invasive measurements. How-
ever, previous studies demonstrated that there is strong
evidence that the albumin leakage sign in CMR repre-
sents a surrogate marker for endothelial damage (8,9).
Only a relatively small number of patients was included
in this study. Finally, patients were only catego-
rized based on HbA1c levels and not based on fasting
glycemia. However it has been shown that HbA1c is
a well-established parameter for cardiovascular risk
stratification (3).
In conclusion, CMR in combination with an albumin-
binding probe suggests that intermediate HbA1c levels
(5.7–6–4%) and high HbA1c levels ($6.5%) are associated
with a greater extent of endothelial damage of the coro-
nary arteries compared with HbA1c levels ,5.7%. Larger
studies are needed to evaluate the impact that this in vivo
parameter could have on treatment strategies and the
associated outcomes of patients.
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